Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.
Status:
Not yet recruiting
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
Most patients with mCRC are treated with palliative chemotherapy and only a small number of
patients with limited metastatic disease achieve long-term remission following
metastasectomy. There is a growing need for more effective treatment in patients with
liver-only mCRC to improve the rate of curative resection without compromising QOL.The
current study is informed by our patient's needs. It aims to evaluate the rate of conversion
therapy in patients with unresectable liver-only mCRC using the combination of FOLFOXIRI and
bevacizumab and to assess the association between an early FDG-PT/CT response and other
clinical and pathological biomarkers and hepatic metastasectomy.